Filetti S, Foti D, Costante G, Rapoport B
Dipartimento di Medicina Sperimentale e Clinica, Université di Reggio Calabria, Catanzaro, Italy.
J Clin Endocrinol Metab. 1991 May;72(5):1096-101. doi: 10.1210/jcem-72-5-1096.
We studied the suitability of using the recombinant human TSH receptor expressed in Chinese hamster ovary cells in a TSH binding inhibition (TBI) assay for autoantibodies against the TSH receptor. Purified immunoglobulin G (IgG) containing potent thyroid-stimulating immunoglobulin bioactivity competed for radiolabeled TSH binding to recombinant TSH receptor in parallel to inhibition by unlabeled TSH. Using polyethylene glycol-prepared IgG, this assay discriminated very well between sera from normal individuals [TBI, 0.98 +/- 0.04 (+/- SD); range, 0.92-1.08; n = 35] and patients with untreated Graves' disease (TBI, 0.49 +/- 0.23; range, 0.06-0.98; n = 93). Only four of the sera from the untreated Graves' patients were TBI negative (greater than or equal to 0.92), providing a sensitivity of 96%. In sera from patients with Graves' disease receiving antithyroid drug therapy, TBI was 0.63 +/- 0.18 (range, 0.19-0.97; n = 75). In this group of treated patients, 2 of 75 were TBI negative. Four of 12 patients with Hashimoto's thyroiditis (33%) were positive for TBI activity. All 18 patients with nonautoimmune thyroid diseases (toxic nodular goiter, single toxic adenoma, subacute thyroiditis, or thyroid cancer) were TBI negative. Correlation of the TBI values with thyroid-stimulating immunoglobulin bioactivity revealed a generally positive correlation (r = 0.31; P less than 0.05); however, there were many discrepancies among individual sera. TSI bioactivity was undetectable in all 4 patients with Hashimoto's thyroiditis who were TBI positive. These data indicate that the recombinant TSH receptor in Chinese hamster ovary cells is a suitable system for detecting TBI activity in the sera of patients with autoimmune thyroid disease.
我们研究了在中国仓鼠卵巢细胞中表达的重组人促甲状腺激素（TSH）受体用于检测抗TSH受体自身抗体的TSH结合抑制（TBI）试验的适用性。含有强效促甲状腺免疫球蛋白生物活性的纯化免疫球蛋白G（IgG）与放射性标记的TSH竞争结合重组TSH受体，其效果与未标记TSH的抑制作用平行。使用聚乙二醇制备的IgG，该试验能够很好地区分正常个体的血清[TBI，0.98±0.04（±标准差）；范围，0.92 - 1.08；n = 35]和未经治疗的格雷夫斯病患者的血清（TBI，0.49±0.23；范围，0.06 - 0.98；n = 93）。未经治疗的格雷夫斯病患者的血清中只有4份TBI阴性（≥0.92），灵敏度为96%。在接受抗甲状腺药物治疗的格雷夫斯病患者的血清中，TBI为0.63±0.18（范围，0.19 - 0.97；n = 75）。在这组接受治疗的患者中，75例中有2例TBI阴性。12例桥本甲状腺炎患者中有4例（33%）TBI活性呈阳性。所有18例非自身免疫性甲状腺疾病（毒性结节性甲状腺肿、单个毒性腺瘤、亚急性甲状腺炎或甲状腺癌）患者的TBI均为阴性。TBI值与促甲状腺免疫球蛋白生物活性的相关性显示总体呈正相关（r = 0.31；P < 0.05）；然而，个体血清之间存在许多差异。在所有4例TBI阳性的桥本甲状腺炎患者中均未检测到TSI生物活性。这些数据表明，中国仓鼠卵巢细胞中的重组TSH受体是检测自身免疫性甲状腺疾病患者血清中TBI活性的合适系统。
